First report of post-transplant autoimmune hepatitis recurrence following SARS-CoV-2 mRNA vaccination

Whilst vaccination for the SARS-CoV-2 virus has been successful in reducing the severity and burden of the COVID-19 pandemic, there have been recent reports of mRNA vaccines triggering autoimmune hepatitis in the native liver. There have been no descriptions thus far of recurrent ‘autoimmune hepatit...

Full description

Saved in:
Bibliographic Details
Published inTransplant immunology Vol. 72; p. 101600
Main Authors Mahalingham, Aarani, Duckworth, Adam, Griffiths, William J.H.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.06.2022
Published by Elsevier B.V
Subjects
Autoimmune hepatitis
Brief Communication
Liver transplantation
mRNA vaccine
SARS-CoV2
SARS-CoV2
Autoimmune hepatitis
mRNA vaccine
Liver transplantation
Online AccessGet full text

Cover

More Information
Summary:Whilst vaccination for the SARS-CoV-2 virus has been successful in reducing the severity and burden of the COVID-19 pandemic, there have been recent reports of mRNA vaccines triggering autoimmune hepatitis in the native liver. There have been no descriptions thus far of recurrent ‘autoimmune hepatitis’ after liver transplantation in the context of SARS-CoV-2 vaccination. We describe a patient transplanted for autoimmune hepatitis who was stable for many years until they had immune-mediated flares coinciding with Pfizer-BioNTech mRNA vaccination. Intravenous steroid treatment was required to suppress histologically evident interface hepatitis. We firmly believe that mRNA vaccination was responsible for this ‘recurrence’ and that clinicians should be vigilant for this reaction in patients transplanted for autoimmune hepatitis.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0966-3274
1878-5492
DOI:10.1016/j.trim.2022.101600